Till startsida
University of Gothenburg
Sitemap
To content Read more about how we use cookies on gu.se

Group Eva Forsell Aronsson

Research summary

Many tumour types are difficult to cure, especially metastatic disease. Therapy using radiopharmaceuticals could then be useful, due to the possibility to reach also tumour cells spread in the body. New knowledge regarding tumour biology, pathology and molecular biology demonstrate more tumour specific features/biomarkers that can be used for development of more specific radiopharmaceuticals and treatment strategies.

Our aim is to study the possibilities to develop, optimise and apply new radiopharmaceuticals for therapy, and to optimise treatment protocols. Some of the specific aims are:
 

  1. to optimise treatment with radiolabelled hormone analogues for hormone receptor-expressing tumours.
     
  2. to optimise radioiodine therapy of highly differentiated thyroid tumours e.g. regarding the stunning phenomenon.
     
  3. to define possible biomarkers for radiotoxicity in tumour and normal tissues.
     
  4. to optimise radionuclide therapy by using enhanced knowledge based on basal molecular studies of radiobiological effects on tumour tissue and critical normal tissues.
     
  5. to enhance the knowledge on radiation dosimetry and tolerance doses for radionuclide therapy in critical normal tissues.
     

Much research is done using the radiolabelled somatostatin analogue 177Lu-octreotate for therapy of neuroendocrine tumours expressing somatostatin receptors.

We try to increase the radiobiological effects on tumour tissue by using optimal fractionation schedules, increasing the receptor expression, reducing saturation of receptors, combination with other agents (radiosenstizing). We try to reduce the side effects on critical normal tissues, e.g by reducing kidney uptake and kidney toxicity. We also try to find biomarkers for radiobiological effects (toxicity) on tumour and normal tissues.

Research tools and resources

We perform studies on cell culture, mice and rats and patients. Pharmacokinetic and dosimetric studies are performed in tumour-bearing animals and man. Studies on toxicity and biological effects (animals) utilizes e.g imaging techniques (scintigraphy, MRI), histopathology and gene expression analysis.

Current group members

Eva Forssell-Aronsson, PhD, Professor
Britta Langen, PhD, Researcher
Emman Shubbar, PhD, Researcher
Mikael Montelius, PhD, Researcher
Johan Spetz, PhD, Researcher
Arman Romiani, PhD-student
Charlotte Andersson, PhD-student
Ingun Ståhl, PhD-student
Malin Larsson, PhD-student
Mikael Elvborn, PhD-student
Viktor Sandblom, PhD-student
Sofia Saadati, PhD-student
Lukas Lundholm, Research Associate
 

The Forssell-Aronsson Lab is also part of Sahlgrenska Translational Neuroendocrine Cancer Group (SATNEC).

 

Group Forsell-Aronsson publications on PubMed

 

SATNEC

Read more about Sahlgrenska Translational Neuroendocrine Cancer Group and its activities.

Contact information

Eva Forssell-Aronsson

E-mail: Eva Forssell-Aronsson
Phone: +46 (0)31 342 2349

Visiting address:
Sahlgrenska University Hospital
Gula stråket 2B
413 45 Göteborg

Page Manager: Yael Zukovsky Fitoussi|Last update: 2/28/2019
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?